Ravoxertinib also known as GDC-0994 and RG7842, is an orally available inhibitor of extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon oral administration, GDC-0994 inhibits both ERK phosphorylation and activation of ERK-mediated signal transduction pathways. This prevents ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.
ERK Inhibitors Related Products:
BIX02189; Resveratrol; SCH772984; Pluripotin; VX-11e; DEL-22379; Ulixertinib; XMD8-92; Bosutinib; ERK5-IN-1; ONC-201; AZD-0364